These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 26523360

  • 21. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H, Ross H.
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [Abstract] [Full Text] [Related]

  • 22. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I, Zaruba MM, Beiras-Fernandez A, Reimann R, Nickel T, Grinninger C, Sadoni S, Hagl C, Meiser B.
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [Abstract] [Full Text] [Related]

  • 23. Terminal Ileac Ulcers Mimicked Post-transplantation Lymphoproliferative Disorder in a Heart Recipient Treated With Everolimus: A Case Report.
    Iwasaki K, Seguchi O, Mochizuki H, Kimura Y, Toda K, Kumai Y, Kuroda K, Nakajima S, Watanabe T, Yanase M, Matsumoto Y, Fukushima S, Fujita T, Kobayashi J, Fukushima N.
    Transplant Proc; 2018 Dec; 50(10):4053-4056. PubMed ID: 30577313
    [Abstract] [Full Text] [Related]

  • 24. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
    Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ, Shun CT.
    Transplant Proc; 2010 Apr; 42(3):938-9. PubMed ID: 20430209
    [Abstract] [Full Text] [Related]

  • 25. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
    Mirza K, Gustafsson F, Gullestad L, Arora S, Andersen C.
    Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
    [Abstract] [Full Text] [Related]

  • 26. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine.
    Taylor DO, Sharma RC, Kfoury AG, Renlund DG.
    Clin Transplant; 1999 Aug; 13(4):296-9. PubMed ID: 10485369
    [Abstract] [Full Text] [Related]

  • 27. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 28. Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.
    Rosing K, Fobker M, Kannenberg F, Gunia S, Dell'Aquila AM, Kwiecien R, Stypmann J, Nofer JR.
    Atherosclerosis; 2013 Sep 15; 230(1):164-70. PubMed ID: 23958269
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effect of high-intensity interval training on progression of cardiac allograft vasculopathy.
    Nytrøen K, Rustad LA, Erikstad I, Aukrust P, Ueland T, Lekva T, Gude E, Wilhelmsen N, Hervold A, Aakhus S, Gullestad L, Arora S.
    J Heart Lung Transplant; 2013 Nov 15; 32(11):1073-80. PubMed ID: 23906899
    [Abstract] [Full Text] [Related]

  • 33. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C, Dengler T, Hack MA, Ladenburger S, Lehmkuhl HB.
    Transplant Proc; 2013 Nov 15; 45(6):2387-92. PubMed ID: 23953553
    [Abstract] [Full Text] [Related]

  • 34. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb 15; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 35. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
    Loriga G, Ciccarese M, Pala PG, Satta RP, Fanelli V, Manca ML, Serra G, Dessole P, Cossu M.
    Transplant Proc; 2010 May 15; 42(4):1297-302. PubMed ID: 20534285
    [Abstract] [Full Text] [Related]

  • 36. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation.
    Zuckermann A, Arizon JM, Dong G, Eisen HJ, Kobashigawa J, Lehmkuhl H, Ross H, Pelligrini C, Wang SS, Barten MJ.
    Transplantation; 2011 Sep 15; 92(5):594-600. PubMed ID: 21862955
    [Abstract] [Full Text] [Related]

  • 37. Conversion to everolimus in pediatric heart transplant recipients is a safe treatment option with an impact on cardiac allograft vasculopathy and renal function.
    Grimm K, Lehner A, Fernandez Rodriguez S, Orban M, Fischer M, Rosenthal LL, Jakob A, Haas NA, Dalla Pozza R, Kozlik-Feldmann R, Ulrich SM.
    Clin Transplant; 2021 Mar 15; 35(3):e14191. PubMed ID: 33315277
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.
    Billing H, Burmeister G, Plotnicki L, Ahlenstiel T, Fichtner A, Sander A, Höcker B, Tönshoff B, Pape L.
    Transpl Int; 2013 Sep 15; 26(9):903-9. PubMed ID: 23865768
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.